Last reviewed · How we verify
Empagliflozin + Carvedilol
This combination reduces blood glucose via SGLT2 inhibition while simultaneously lowering heart rate and blood pressure through beta-blockade.
This combination reduces blood glucose via SGLT2 inhibition while simultaneously lowering heart rate and blood pressure through beta-blockade. Used for Type 2 diabetes mellitus with cardiovascular disease or heart failure, Hypertension in diabetic patients.
At a glance
| Generic name | Empagliflozin + Carvedilol |
|---|---|
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Drug class | SGLT2 inhibitor + non-selective beta-blocker combination |
| Target | SGLT2 and beta-adrenergic receptors (β1, β2, α1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular and Diabetes |
| Phase | FDA-approved |
Mechanism of action
Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, promoting urinary glucose excretion and lowering blood glucose independently of insulin. Carvedilol is a non-selective beta-adrenergic receptor antagonist that reduces heart rate, contractility, and blood pressure. Together, they provide complementary cardiovascular and metabolic benefits in diabetic patients.
Approved indications
- Type 2 diabetes mellitus with cardiovascular disease or heart failure
- Hypertension in diabetic patients
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Hypotension
- Fatigue
- Dizziness
- Bradycardia
Key clinical trials
- HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy (PHASE2)
- A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis (NA)
- DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis (PHASE4)
- An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
- RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy (NA)
- Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction (PHASE4)
- Pharmacological Reduction of Right Ventricular Enlargement (PHASE3)
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD " (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: